| pubmed-article:19846979 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19846979 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19846979 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:19846979 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:19846979 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:19846979 | lifeskim:mentions | umls-concept:C1879771 | lld:lifeskim |
| pubmed-article:19846979 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:19846979 | pubmed:dateCreated | 2009-10-22 | lld:pubmed |
| pubmed-article:19846979 | pubmed:abstractText | To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of BIBF 1120, a triple angiokinase inhibitor administered once-daily in patients with advanced multiple myeloma. | lld:pubmed |
| pubmed-article:19846979 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19846979 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19846979 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19846979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19846979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19846979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19846979 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19846979 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:19846979 | pubmed:issn | 1791-7530 | lld:pubmed |
| pubmed-article:19846979 | pubmed:author | pubmed-author:BerdelWolfgan... | lld:pubmed |
| pubmed-article:19846979 | pubmed:author | pubmed-author:KropffMartinM | lld:pubmed |
| pubmed-article:19846979 | pubmed:author | pubmed-author:KienastJoachi... | lld:pubmed |
| pubmed-article:19846979 | pubmed:author | pubmed-author:MunzertGerdG | lld:pubmed |
| pubmed-article:19846979 | pubmed:author | pubmed-author:StopferPeterP | lld:pubmed |
| pubmed-article:19846979 | pubmed:author | pubmed-author:BispingGuidoG | lld:pubmed |
| pubmed-article:19846979 | pubmed:author | pubmed-author:Gaschler-Mark... | lld:pubmed |
| pubmed-article:19846979 | pubmed:author | pubmed-author:StefanicMarti... | lld:pubmed |
| pubmed-article:19846979 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19846979 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:19846979 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19846979 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19846979 | pubmed:pagination | 4233-8 | lld:pubmed |
| pubmed-article:19846979 | pubmed:meshHeading | pubmed-meshheading:19846979... | lld:pubmed |
| pubmed-article:19846979 | pubmed:meshHeading | pubmed-meshheading:19846979... | lld:pubmed |
| pubmed-article:19846979 | pubmed:meshHeading | pubmed-meshheading:19846979... | lld:pubmed |
| pubmed-article:19846979 | pubmed:meshHeading | pubmed-meshheading:19846979... | lld:pubmed |
| pubmed-article:19846979 | pubmed:meshHeading | pubmed-meshheading:19846979... | lld:pubmed |
| pubmed-article:19846979 | pubmed:meshHeading | pubmed-meshheading:19846979... | lld:pubmed |
| pubmed-article:19846979 | pubmed:meshHeading | pubmed-meshheading:19846979... | lld:pubmed |
| pubmed-article:19846979 | pubmed:meshHeading | pubmed-meshheading:19846979... | lld:pubmed |
| pubmed-article:19846979 | pubmed:meshHeading | pubmed-meshheading:19846979... | lld:pubmed |
| pubmed-article:19846979 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19846979 | pubmed:articleTitle | An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma. | lld:pubmed |
| pubmed-article:19846979 | pubmed:affiliation | Department of Medicine/Haematology and Oncology, University of Muenster Albert-Schweitzer-Str. 33, D-48129 Muenster, Germany. martin.kropff@ukmuenster.de | lld:pubmed |
| pubmed-article:19846979 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19846979 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19846979 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
